Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel; The Gastroenterology Unit, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Clin Immunol. 2021 Jun;227:108723. doi: 10.1016/j.clim.2021.108723. Epub 2021 Apr 7.
Severe acute respiratory syndrome coronavirus 2 infected patients, receiving background anti-CD20 therapy, were treated with convalescent plasma or plasma-based products. Eight patients were included in the study, presenting with prolonged disease course and delayed viral clearance. CP/plasma-based products were offered as an add-on therapy to standard medical treatment. All patients showed remarkable clinical and laboratory improvement. In addition, polymerase chain reaction from nasopharyngeal swabs rapidly converted to negative following plasma administration. This study emphasizes the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion.
严重急性呼吸综合征冠状病毒 2 感染患者在接受背景抗 CD20 治疗的同时，接受了恢复期血浆或基于血浆的产品治疗。本研究纳入了 8 例患者，这些患者表现为疾病持续时间延长和病毒清除延迟。CP/基于血浆的产品作为标准治疗的附加治疗方法。所有患者的临床和实验室指标均显著改善。此外，在给予血浆后，鼻咽拭子的聚合酶链反应迅速转为阴性。本研究强调了恢复期血浆和基于血浆的产品在因医源性 B 细胞耗竭而免疫功能低下的患者亚组中的治疗效果。
